Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Plc Regulatory News (ZTF)

Share Price Information for Zotefoams Plc (ZTF)

Share Price is delayed by 15 minutes
Get Live Data
434.50    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 2.50 (0.578%)
Market Cap: £213.70m
ZTF Live PriceLast checked at - London Stock Exchange

Intraday Zotefoams Plc Share Chart

Trading Update

17 May 2017 07:00

RNS Number : 3523F
Zotefoams PLC
17 May 2017
 

Zotefoams plc

("Zotefoams" or "the Company")

 

Trading Update

 

 

17th May 2017 - Zotefoams, a world leader in cellular materials technology, today provides a trading update for the first quarter ended 31 March 2017, ahead of its Annual General Meeting at 675 Mitcham Road, Croydon CR9 3AL at 10am. At this meeting Steve Good, Chairman of Zotefoams plc, will make the following statement:

 

"Group revenue for the first three months of the year was in line with management expectations, being approximately 28% ahead of the comparative period for the previous year and delivering a record sales result for the first quarter. Revenue from Polyolefin foams increased by 6% at constant currency with capacity improvements, following recent investments, allowing us to meet increased demand levels. High Performance Products sales benefitted from increased demand for ZOTEK ® PEBA, while the high-value MuCell equipment contract, delayed from 2016, shipped in the quarter. At constant currency, overall revenue growth was around 16% ahead of the comparative period for the previous year.

 

In Walton, Kentucky, USA, the previously delayed high-pressure autoclave was delivered and passed its final acceptance testing in April this year. The business is working hard to complete the project and is now anticipating a start-up around the end of the third quarter. Once operational, this investment will deliver approximately 20% additional global capacity.

 

While it is still early in the year, and we are mindful of the less stable political and macroeconomic environment, we continue to expect 2017 to be another year of progress and remain confident about the long-term prospects of the business."

 

- Ends -

 

Enquiries:

 

Zotefoams plc

+44 (0)208 664 1600

David Stirling, Group CEO

Gary McGrath, Finance Director

FTI Consulting

+44 (0)203 727 1000

Victoria Foster Mitchell / Simon Conway

 

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology. Using a unique manufacturing process with environmentally friendly nitrogen expansion, Zotefoams produces and sells lightweight AZOTE® polyolefin and ZOTEK® high-performance foams for diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets. In addition, Zotefoams owns and licenses patented MuCell® microcellular foam technology, developed specifically for extrusion applications, from a base in Massachusetts, USA to customers worldwide.

 

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky and Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA (MuCell Extrusion) and Jiangsu Province, China (T-FIT®).

 

www.zotefoams.com

 

AZOTE®, ZOTEK®, T-FIT® are registered trademarks of Zotefoams plc

MuCell® is a registered trademark of Trexel Inc.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTFMGMKGVVGNZZ
Date   Source Headline
6th May 20207:00 amRNS2019 Annual Report and Notice of the 2020 AGM
28th Apr 20204:39 pmRNSDisclosure of rights attached to equity shares
22nd Apr 20203:51 pmRNSDirector/PDMR Shareholding
16th Apr 202012:39 pmRNSDirector/PDMR Shareholding
14th Apr 20202:41 pmRNSDirector/PDMR Shareholding
8th Apr 20204:19 pmRNSDirector/PDMR Shareholding
7th Apr 20207:00 amRNSPreliminary Results
1st Apr 20207:00 amRNSNotice of Results
31st Mar 202012:07 pmRNSSecond Price Monitoring Extn
31st Mar 202012:02 pmRNSPrice Monitoring Extension
24th Mar 20207:00 amRNS2019 Summary, COVID-19 and Current Trading Update
23rd Mar 20207:00 amRNSDelayed Preliminary Results
19th Mar 20208:40 amRNSDirectorate Change
17th Mar 20209:49 amRNSHolding(s) in Company
12th Mar 20204:11 pmRNSDirector/PDMR Shareholding
10th Mar 20204:30 pmRNSNotice of Results
27th Feb 20203:00 pmRNSDirector Declaration
12th Feb 20209:24 amRNSDirector/PDMR Shareholding
21st Jan 20207:00 amRNSYear-End Trading Update
16th Jan 20203:33 pmRNSHolding(s) in Company
13th Jan 20204:21 pmRNSDirector/PDMR Shareholding
27th Dec 20199:03 amRNSHolding(s) in Company
17th Dec 20199:34 amRNSDirector/PDMR Shareholding
13th Dec 20198:41 amRNSHolding(s) in Company
3rd Dec 20197:00 amRNSHolding(s) in Company
26th Nov 201910:39 amRNSHolding(s) in Company
13th Nov 20193:09 pmRNSDirector/PDMR Shareholding
15th Oct 20192:50 pmRNSNOTIFICATION OF TRANSACTIONS OF DIRECTORS/PDMRs
15th Oct 20199:48 amRNSNOTIFICATION OF TRANSACTIONS OF DIRECTORS/PDMRs
15th Oct 20197:00 amRNSDirector/PDMR Shareholding
11th Oct 20194:31 pmRNSHolding(s) in Company
9th Oct 20192:37 pmRNSDirector/PDMR Shareholding
9th Oct 20197:00 amRNSNew technology for recyclable packaging
8th Oct 20197:00 amRNSAppointment of Joint Broker
3rd Oct 20197:00 amRNSTrading Update
1st Oct 201911:47 amRNSDirector Declaration
16th Sep 20193:39 pmRNSDirector/PDMR Shareholding
6th Sep 201912:07 pmRNSSecond Price Monitoring Extn
6th Sep 201912:02 pmRNSPrice Monitoring Extension
27th Aug 201912:07 pmRNSSecond Price Monitoring Extn
27th Aug 201912:02 pmRNSPrice Monitoring Extension
21st Aug 201912:07 pmRNSSecond Price Monitoring Extn
21st Aug 201912:02 pmRNSPrice Monitoring Extension
13th Aug 20193:26 pmRNSDirector/PDMR Shareholding
6th Aug 20197:00 amRNSInterim Results
15th Jul 20194:31 pmRNSDirector/PDMR Shareholding
12th Jul 20193:51 pmRNSDirector/PDMR Shareholding
10th Jul 20194:22 pmRNSHolding(s) in Company
9th Jul 20197:00 amRNSNotice of Results
12th Jun 20192:53 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.